STOCK TITAN

Investor Notice: Feb 28th Deadline for certain Investors in Instadose Pharma Corp. shares announced by Shareholders Foundation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Negative)
Tags

SAN DIEGO, Feb. 16, 2022 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a deadline is coming up on February 28, 2022, in the lawsuit that was filed for certain investors in OTC: INSD shares.

Investors who have losses of over $100,000 from their investment in shares of Instadose Pharma Corp. (OTC: INSD) have certain options and there are short and strict deadlines running. Deadline: February 28, 2022. Those OTC: INSD investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On December 30, 2021, a lawsuit was filed against Instadose Pharma Corp. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that Instadose had performed inadequate due diligence into the Business Combination and/or ignored significant red flags associated with Instadose Canada, that Instadose's internal controls and policies were inadequate to detect and/or prevent impermissible trading activity by control persons of the Company, that the foregoing subjected Instadose to a heightened risk of regulatory scrutiny and enforcement action, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Instadose Pharma Corp. (OTC: INSD) should contact the Shareholders Foundation, Inc.

CONTACT:
Shareholders Foundation, Inc. 
Michael Daniels 
+1 (858) 779-1554 
mail@shareholdersfoundation.com 
3111 Camino Del Rio North 
Suite 423 
San Diego, CA 92108

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-notice-feb-28th-deadline-for-certain-investors-in-instadose-pharma-corp-shares-announced-by-shareholders-foundation-301483383.html

SOURCE Shareholders Foundation, Inc.

Instadose Pharma Corp

OTC:INSD

INSD Rankings

INSD Latest News

INSD Stock Data

About INSD

instadose pharma corp. (“instadose”) is becoming the largest producer of cannabis oil in the world with a present projected cultivation capacity of over 2,250,000 kg of high-grade 97.0% isolate cbd and 92% isolate thc per year. global leader in cannabis production & commercial distribution of cannabinoid oil leading the disruption of the global cannabis industry by turning cannabis and cannabinoid oil into an insurable commodity exclusive right and license to grow, cultivate, and process (for export and sale) medical pharmaceutical cannabis in the drc 50-year partnerships with the newly elected drc government & the saccos (the region's largest farming co-operative) - gives instadose 1,000,000+ hectares (ha) of land in the aggregate for cannabis production & cultivation existing 5-year supply agreements for cannabinoid oil with leading global buyers generating usd$5b+ in revenue to instadose gmp certified & pharmaceutically accredited with eu pharmacopoeia standards talented and r